The condensed balance sheet as of December 31, 2023 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed ...
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...
Sutro’s pool chemistry monitor is wildly expensive and has a few too many limitations for us to recommend it over less-expensive solutions. Owning a pool is like owning any other high-dollar product: ...
Ratings for Sutro Biopharma (NASDAQ:STRO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...
Webcasts of the fireside chats at the TD Cowen and Citizens conferences will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at ...
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results